

# 30<sup>th</sup> Symposium on Medicinal Chemistry in Eastern England Celebrating UK Drug Discovery


Thursday 2<sup>nd</sup> May 2019
Fielder Centre,

Hatfield, Hertfordshire, UK



# **Synopsis**

2019 represents the 30th anniversary of the Symposium on Medicinal Chemistry in Eastern England, known colloquially as the "Hatfield MedChem" meeting. This is a highly successful, long-standing, one-day annual meeting. To commemorate 30 years, the programme will focus on 'Celebrating UK Drug Discovery', highlighting success stories from large pharma, biotech and academia; and exciting scientific prospects for the future. Presentations will showcase medicinal chemistry from tools to candidates, across a range of modalities, therapeutic areas and target classes with an emphasis on key learnings and knowledge developed during the course of effective discovery efforts. The meeting aims to be informal and interactive and will offer excellent scientific development and



Twitter Hashtag

#HatfieldMedChem19

Call for Posters

Applications are invited for poster

presentation. Posters will be

displayed throughout the day.

Closing date is 2nd March.

networking opportunities for all those working in medicinal chemistry and drug discovery.

## **Programme**

- 09.00 Registration, refreshments and exhibition
- 09.30 Welcome and introduction
- 09.35 <u>Keynote Presentation</u>: *Drug discovery past, present and future*: a personal perspective **Julian Blagg**, Neophore and Azeria Therapeutics
- 10.10 A journey into CNS drug discovery Luis Castro, UCB
- 10.45 Refreshments and exhibition
- 11.10 Drugs from host-guest chemistry in Scotland and fragments in England David Rees,
  Astex Pharmaceuticals
- 11.45 Multifunctional PROTACs: protein degradation with a twist Ed Tate, Imperial College London and Crick Institute
- 12.10 Bicycles® an entirely new class of therapies
  Paul Beswick, Bicycle Therapeutics
- 12.35 Lunch and exhibition
- 13.30 <u>Capps Green Zomaya Award presentation lecture</u>:

  The covalent targeting of cysteine residues in drug discovery and its application to the discovery of Osimertinib Richard A Ward, AstraZeneca
- 14.05 Discovery of three generations of selective beta-2 agonists, from salbutamol to vilanterol Diane Coe, GlaxoSmithKline, UK
- 14.40 Phenotypic activity driven target identification and discovery of drug candidates
  Paul Wyatt, Drug Discovery Unit, University of Dundee
- 15.05 Refreshments and exhibition
- 15.30 Antivirals: Safety: Antivirals the best sandwich David Price, Pfizer
- 16.05 Application of structure-based drug discovery to G protein-coupled receptors Miles Congreve, Sosei Heptares
- 16.30 When the rubber hits the road: a case study of AI applied to ALS Drug Discovery Mark Rackham, BenevolentAI
- 16.55 Concluding remarks and close (at 17.00)

# Registration and Bursaries

Registration will be open shortly, and some student bursaries are available.

### **Secretariat Contact**

Maggi Churchouse Events
Telephone: +44 (0)1359 221004
maggi@maggichurchouseevents.co.uk

## **Sponsors**

Sponsors are encouraged to support this popular event.



# **Organising Committee**

Adrian Hall, UCB (Treasurer) Nicole Hamblin, Charles River (Chair) David Hirst, GlaxoSmithKline

Website: www.maggichurchouseevents.co.uk/bmcs (also www.rsc.org/bmcs)